Yayın:
Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorTurhal, Serdar
dc.contributor.authorMükremın Uysal
dc.contributor.authorSerkan Menekşe
dc.contributor.authorSemih Akin
dc.contributor.authorFatih Yıldız
dc.contributor.authorMerve Turan
dc.contributor.authorSema Sezgin Göksu
dc.contributor.authorİsmail Beypınar
dc.contributor.authorTeoman Şakalar
dc.contributor.authorMustafa Değirmenci
dc.contributor.authorDi̇lek Erdem
dc.contributor.authorGül Başaran
dc.contributor.authorÖmer Fatih Ölmez
dc.contributor.authorNilüfer Avcı
dc.contributor.authorDeniz Tural
dc.contributor.authorAbdullah Sakin
dc.contributor.authorSema Türker
dc.contributor.authorAtakan Demir
dc.contributor.authorSüleyman Temiz
dc.contributor.authorKaplan Ma
dc.contributor.authorMutlu Doğan
dc.contributor.authorÖzgür Tanrıverdi
dc.contributor.authorİrem Bilgetekin
dc.contributor.authorHavva Yeşil Çınkır
dc.contributor.authorÖzgür Açıkgöz
dc.contributor.authorSemra Paydaş
dc.contributor.authorRüçhan Uslu
dc.contributor.authorSerdar Turhal
dc.contributor.orcid0000-0002-0443-6966
dc.contributor.orcid0000-0002-8524-0665
dc.contributor.orcid0000-0002-2134-2128
dc.contributor.orcid0000-0002-3644-7133
dc.contributor.orcid0000-0003-2295-7332
dc.contributor.orcid0000-0003-4021-6095
dc.contributor.orcid0000-0002-8026-764X
dc.contributor.orcid0000-0002-0853-4096
dc.contributor.orcid0000-0003-2749-9414
dc.contributor.orcid0000-0001-6988-9205
dc.contributor.orcid0000-0001-6495-6712
dc.contributor.orcid0000-0002-0775-6180
dc.contributor.orcid0000-0001-7934-7039
dc.contributor.orcid0000-0003-2144-6469
dc.contributor.orcid0000-0003-2538-8569
dc.contributor.orcid0000-0001-9040-7266
dc.contributor.orcid0000-0002-1940-4086
dc.contributor.orcid0000-0003-0882-0524
dc.contributor.orcid0000-0001-9359-3770
dc.contributor.orcid0000-0002-0598-7284
dc.contributor.orcid0000-0003-1154-5850
dc.contributor.orcid0000-0002-7870-8741
dc.contributor.orcid0000-0003-2715-4002
dc.contributor.orcid0000-0003-4642-3693
dc.contributor.orcid0000-0002-9584-6134
dc.date.accessioned2025-11-13T11:56:11Z
dc.date.issued2021-12-11
dc.identifier.doihttps://doi.org/10.1080/07357907.2021.2017952
dc.identifier.endpage209
dc.identifier.issn0735-7907
dc.identifier.issue2
dc.identifier.openalexW4200357507
dc.identifier.startpage199
dc.identifier.urihttps://hdl.handle.net/11421/8433
dc.identifier.urihttps://doi.org/10.1080/07357907.2021.2017952
dc.identifier.volume40
dc.language.isoen
dc.relation.ispartofCancer Investigation
dc.rightsrestrictedAccess
dc.subjectMedicine
dc.subjectMetastatic breast cancer
dc.subjectExemestane
dc.subjectInternal medicine
dc.subjectOncology
dc.subjectEverolimus
dc.subjectHormone receptor
dc.subjectProgression-free survival
dc.subjectBreast cancer
dc.subjectCancer
dc.subjectGynecology
dc.subjectAromatase
dc.subjectChemotherapy
dc.subject.sdg1
dc.titleReal-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5108484042

Dosyalar

Koleksiyonlar

Publications